Minal Barve is an Oncology physician affiliated with Mary Crowley Cancer Research Center. OpenAlex indexes 418 publications with 7,336 citations (h-index 33); ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8220 Walnut Hill Ln
Suite 700
Dallas, TX 752314427
Telephone
214-739-4175Registry record last updated 14 Aug 2014.
Clinical trials
- HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
Sponsor: HighField Biopharmaceuticals Corporation
- Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Sponsor: Intezyne Technologies, Inc.
- Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Sponsor: Mary Crowley Medical Research Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CATALYST PHARMACEUTICALS, INC.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
- JAZZ PHARMACEUTICALS INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
39.8%Parenteral Iron Replacement22.5%Iron sucrose100%Part B, office-administered≥26 patientsErythropoiesis-stimulating Agent17%Darbepoetin alfa100%Part B, office-administered≥25 patients+ 3 more classes in this area
Metabolism & gastrointestinal
30%Other antiemetics25.9%Fosaprepitant100%Part B, office-administered≥39 patientsSerotonin-3 Receptor Antagonist3.9%Palonosetron hcl58%Granisetron hydrochloride41%Ondansetron Hcl1%Ondansetron Odt1%Part D + Part B<11 patients+ 3 more classes in this area
Cancer & immunology
16.2%Microtubule Inhibitor13.4%Paclitaxel100%Part B, office-administered≥15 patientsNucleoside Metabolic Inhibitor1%Fluorouracil63%Gemcitabine hydrochloride37%Part B, office-administered≥15 patients+ 9 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”